Search results for "revascularization"

showing 10 items of 159 documents

Assessing the Effects of VEGF Releasing Microspheres on the Angiogenic and Foreign Body Response to a 3D Printed Silicone-Based Macroencapsulation De…

2021

Macroencapsulation systems have been developed to improve islet cell transplantation but can induce a foreign body response (FBR). The development of neovascularization adjacent to the device is vital for the survival of encapsulated islets and is a limitation for long-term device success. Previously we developed additive manufactured multi-scale porosity implants, which demonstrated a 2.5-fold increase in tissue vascularity and integration surrounding the implant when compared to a non-textured implant. In parallel to this, we have developed poly(ε-caprolactone-PEG-ε-caprolactone)-b-poly(L-lactide) multiblock copolymer microspheres containing VEGF, which exhibited continued release of bioa…

RS1-441angiogenesisPharmacy and materia medicadiabetesmedical devicemulti-scale porositydiabetes; prevascularization; drug delivery; VEGF; medical device; multi-scale porosity; angiogenesisSettore BIO/10 - Biochimicadrug deliveryPharmaceutical ScienceprevascularizationVEGFArticlePharmaceutics
researchProduct

Prognostic differences between routine invasive and conservative strategies for the management of high-risk, non-ST segment acute coronary syndromes:…

2007

Abstract Background The optimal revascularization strategy for non-ST elevation acute coronary syndromes (NSTE-ACS) remains controversial, especially in a real world context. The objective of this work was to assess differences at 1 year in all-cause mortality and the composite endpoint of mortality or acute myocardial infarction (MI) between two management strategies for NSTE-ACS: a conservative strategy (CS) versus a routine invasive strategy (RIS). Methods Of 799 consecutive patients admitted to our institution, 369 were treated with CS (from January 2001 to October 2002); 430 patients admitted with the same diagnosis were treated with RIS (from November 2002 to November 2004). A propens…

Relative risk reductionmedicine.medical_specialtyeducation.field_of_studybusiness.industrymedicine.medical_treatmentMortality ratePopulationContext (language use)Revascularizationmedicine.diseaseLower riskMedication prescriptionSurgeryInternal medicineInternal MedicinemedicineMyocardial infarctionbusinesseducationEuropean Journal of Internal Medicine
researchProduct

When, why, and how to perform wire-based antegrade dissection and reentry technique

2022

Antegrade dissection and reentry (ADR) refers to an attempt to cross a coronary chronic total occlusion (CTO) lesion through wire and/or equipment passage in the subintimal space followed by reentry to the distal true lumen. From the original subintimal tracking and reentry (STAR) technique description by Colombo in 2005, refinement of the technique, improved characteristics of the microcatheters and wires, and better understanding of subadventitial vessel trauma have led to higher success rates, lower complications rates, and improved long-term outcomes. In this chapter, we discuss the technique, its outcomes, and limitations.

RevascularizationAntegrade dissection reentry (ADR) techniqueSubintimal tracking and reentry (STAR) techniquesGuidewirePercutaneous coronary intervention (PCI)Chronic total occlusion (CTO)Microcatheter
researchProduct

Rivaroxaban in Peripheral Artery Disease after Revascularization

2020

Abstract Background Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and ...

RivaroxabanAspirinmedicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentGeneral MedicineDisease030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trialMulticenter studylawInternal medicineCardiologyMedicine030212 general & internal medicinebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization

2021

Abstract Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety and effectiveness in LER for PAD. Methods VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespe…

Rivaroxabanmedicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentThrombolysisRevascularizationPlacebomedicine.diseasechemistry.chemical_compoundPaclitaxelchemistryInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the German-Austrian ABSORB RegIstRy.

2021

Aims We aimed to investigate predictors of scaffold failure and the potential impact of an optimized scaffold implantation technique by means of a learning curve on long-term clinical outcome after bioresorbable scaffold (BRS) implantation and to evaluate predictors of scaffold failure. Methods and results A total of 3326 patients were included in this prospective, observational, multi-center study (ClinicalTrials.gov NCT02066623) of consecutive patients undergoing BRS implantation between November 2013 and January 2016. The 3144 patients completed follow-up after 24 months, 3265 patients were eligible for time-to-event-analysis. Clinical endpoints were major adverse cardiac events-a compos…

Scaffoldmedicine.medical_specialtyTime FactorsTarget vessel revascularizationCoronary Artery Disease030204 cardiovascular system & hematologyProsthesis Design03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionAbsorbable ImplantsmedicineClinical endpointHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesbusiness.industryGeneral Medicinemedicine.diseaseThrombosisSurgeryTreatment OutcomeAustriaObservational studyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldMaceCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES
researchProduct

How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology

2020

Atherosclerosis is a systemic disease affecting multiple arterial territories. Patients with clinical atherosclerotic disease in one vascular bed are likely to have asymptomatic or symptomatic atherosclerotic lesions in other vascular beds. Specifically, peripheral arterial disease (PAD) often coexists with coronary and carotid disease. With progression of atherosclerotic disease in one vascular bed, the risk of clinical manifestations in other territories increases and the incidence of adverse cardiovascular events increases substantially with the number of affected vascular beds. Classical risk factors are associated with the development of polyvascular atherosclerotic disease (PVD) in di…

Systemic diseasemedicine.medical_specialtymedicine.medical_treatmentCardiologyDisease030204 cardiovascular system & hematology030230 surgeryRevascularizationAsymptomaticPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansIntensive care medicineAngiologybusiness.industryIncidence (epidemiology)GuidelineAtherosclerosismedicine.diseasePosition papermedicine.symptomCardiology and Cardiovascular MedicinebusinessInternational Angiology
researchProduct

Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre …

2017

Background Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesi…

Target lesionMaleTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary Angiography0302 clinical medicineRisk FactorsNuclear Medicine and ImagingAbsorbable ImplantsClinical endpoint030212 general & internal medicineMyocardial infarctionRegistriesdiabetesClinical performanceGeneral MedicineMiddle AgedThrombosisbioresorbable vascular scaffoldsclinical outcomesEuropeTreatment Outcomebioresorbable vascular scaffolds; clinical outcomes; diabetes; Radiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineCardiologyFemaleRadiologyCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationProsthesis Design03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansRadiology Nuclear Medicine and imagingIn patientEverolimusAgedRetrospective Studiesbusiness.industryCoronary ThrombosisCardiovascular Agentsmedicine.diseaseSurgerybusinessCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy.

2018

BACKGROUND In randomized clinical trials, the risk of thrombotic events with the absorb bioresorbable vascular scaffold (BVS) was significantly higher than with metallic drug-eluting stents. We evaluated predictors of scaffold thrombosis in the large-scale, multicenter German-Austrian ABSORB RegIstRy. METHODS AND RESULTS 3178 patients with treatment of 4252 lesions using 5020 scaffolds were included. Follow-up rate at 6 months was 97.4%. Forty-five (1.42%) patients experienced definite/probable scaffold thrombosis during follow-up. Multiple regression analysis showed implantation of absorb BVS in bifurcation lesions [odds ratio (OR): 4.43; 95% confidence interval (CI): 1.69-11.59; P=0.0024]…

Target lesionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentClinical Decision-MakingCoronary Artery Disease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsGermanyAbsorbable ImplantsMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesAgedbusiness.industryIncidence (epidemiology)Coronary ThrombosisPatient SelectionGeneral MedicineOdds ratioMiddle AgedDebulkingmedicine.diseaseThrombosisConfidence intervalSurgeryTreatment OutcomeAustriaFemaleCardiology and Cardiovascular MedicinebusinessCoronary artery disease
researchProduct

Efficacy of coronary revascularization in patients with acute chest pain managed in a chest pain unit.

2009

To investigate the safety of discharge of patients deemed at low risk of cardiac events after evaluation in a chest pain unit and to determine the prognostic effect of revascularization of patients deemed at high risk.The study population consisted of 1088 patients presenting at the emergency department from January 15, 2001, to September 1, 2006, with chest pain but without ischemia on electrocardiography or troponin elevation. Patients were managed by a chest pain unit protocol that included early exercise testing. Three groups of patients were distinguished: (1) those discharged after exercise testing (424 [39%]); (2) those in whom unstable angina was ruled out after in-hospital evaluati…

ThoraxMalemedicine.medical_specialtyChest Painmedicine.medical_treatmenteducationMyocardial InfarctionChest painRevascularizationInternal medicinemedicineClinical endpointMyocardial RevascularizationHumansMyocardial infarctionAngina Unstablehealth care economics and organizationsAgedPatient dischargebusiness.industryHazard ratioGeneral MedicineMiddle Agedmedicine.diseasePrognosisConfidence intervalPatient DischargeAcute DiseaseCardiologyExercise TestFemaleOriginal Articlemedicine.symptombusinessHospital UnitsMayo Clinic proceedings
researchProduct